Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Femasys Inc
(NQ:
FEMY
)
1.050
+0.040 (+3.96%)
Streaming Delayed Price
Updated: 1:09 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Femasys Inc
< Previous
1
2
Next >
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event
August 19, 2024
Via
ACCESSWIRE
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
August 08, 2024
Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its infertility portfolio
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
June 27, 2024
Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products
From
Femasys Inc.
Via
GlobeNewswire
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
June 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
May 17, 2024
Lee-Sepsick Discussed Company’s FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis
From
Femasys Inc.
Via
GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
May 16, 2024
Lee-Sepsick Discussed Atlanta-Based Biomedical Company’s Women’s Reproductive Health Products
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
May 09, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
May 07, 2024
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting
From
Femasys Inc.
Via
GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
April 18, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
March 28, 2024
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
March 21, 2024
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET...
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
March 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
March 06, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
February 28, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
February 06, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
January 26, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
January 23, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
December 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
November 30, 2023
-- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys --
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
November 28, 2023
From
Femasys Inc.
Via
GlobeNewswire
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
November 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
November 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
November 14, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. EU MDR Final Audit Successfully Completed
October 26, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
October 25, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
October 11, 2023
From
Femasys Inc.
Via
GlobeNewswire
5 of the Most Active Penny Stocks Worth Your Precious Time
October 05, 2023
These are five of the Most Active Penny Stocks in October that investors may find worthy of investment for 2024 and beyond
Via
MarketBeat
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
October 04, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
October 03, 2023
From
Femasys Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.